Research Article Details

Article ID: A11881
PMID: 34267963
Source: Florence Nightingale Hemsire Derg
Title: [Is There an Effect of Dietary Fructose on Development and Prognosis of Chronic Diseases?]
Abstract: Dietary sources of fructose are not only honey, fruit, sucrose, but also high fructose corn syrup in various foods and beverages. Total amount of daily fructose intake is rising by especially increasing use of high fructose corn syrup in the food industry. Fructose can lead to obesity by contributing to high-energy intake and lipogenesis in the body. Depending on the source of fructose, dose and duration, it was involved in de-novo lipid synthesis. Fructose may increase the risk of insulin resistance, non-alcoholic fatty liver and kidney diseases by affecting blood glucose and insulin levels. On the other hand, fructose may initiate inflammatory processes in the organism. In addition to these, fat or salt consisting typical western type diet with high fructose consumption, can increase the potential effect of fructose on chronic diseases. As a result, although it is not fully supported by clinical studies, it is thought that high amounts of fructose intake may increase the risk of chronic disease shown by experimental studies. Also it should be noted that beside high fructose, typical western-style high-fat and high-salt diet may increase the risk of chronic diseases such as obesity, cardiovascular diseases and worsen metabolic syndrome parameters. Furthermore, synthetic fructose, is able to cause some adverse metabolic effects when taken in large amounts; consumption of high amounts of fructose by fruit or honey these negative effects can be either not seen or less observed based on the amount.
DOI: 10.26650/FNJN346677

Strategy ID Therapy Strategy Synonyms Therapy Targets Therapy Drugs
S01 Improve insulin resistance insulin sensitizer; insulin resistance; glucose tolerance Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide Details
S05 Anti-inflammatory inflammatory Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; Details

Target ID Target Name GENE Action Class UniProtKB ID Entry Name

Diseases ID DO ID Disease Name Definition Class
I05 9352 Type 2 diabetes mellitus A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus Details
I14 9970 Obesity An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition Details

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress
D328 Serine Chemical drug DB00133 SRR Improve insulin resistance Under clinical trials Details
D182 Insulin Biological drug DB00030 INSR agonist; CPE modulator&product of -- Under clinical trials Details
D142 Fructose Chemical drug DB04173 -- Intravenous nutrition drug Under clinical trials Details